StockData
Lakefront Biotherapeutics NV logo

Lakefront Biotherapeutics NV (LKFT) stock

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)

Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –

Lakefront Biotherapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was €459.42M, up 37.0% from the year before. Over ten years it grew 13.5% a year on average. The highest annual figure on record is €523.67M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025€459.42M+37.0%
FY2024Dec 31, 2024€335.46M+39.0%
FY2023Dec 31, 2023€241.29M-10.6%
FY2022Dec 31, 2022€269.80M-15.8%
FY2021Dec 31, 2021€320.50M-38.8%
FY2020Dec 31, 2020€523.67M+24.7%
FY2019Dec 31, 2019€420.09M+32.8%
FY2018Dec 31, 2018€316.22M+44.7%
FY2017Dec 31, 2017€218.50M+56.6%
FY2016Dec 31, 2016€139.57M+7.6%
FY2015Dec 31, 2015€129.71M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2021Jun 30, 2021€138.87M+189.4%
Q2 FY2020Jun 30, 2020€147.45M–
Q2 FY2019Jun 30, 2019€94.37M–
Q2 FY2018Jun 30, 2018€81.68M–
Q2 FY2017Jun 30, 2017€47.98M–

More Lakefront Biotherapeutics figures

See a number that looks wrong?